Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, December 2014

Sort by: Newest first Oldest first A-Z Z-A

  • Almus statin reformulation Subscription

    11 DEC 2014 10:46

    The Almus simvastatin 20mg and 40mg tablets have been reformulated. As a result, the product appearance has changed. This change came into effect in September 2014.

  • UK Prime Minister, David Cameron (pictured) commissioned a review to look at the dangers posed by drug-resistant superbugs. The review predicts that 10 million people will die every year by 2050 due to antimicrobial resistance

    Antimicrobial resistance will lead to an additional 10 million deaths each year worldwide by 2050 Subscription

    11 DEC 2014 10:16 By Ingrid Torjesen

    Failure to address growing resistance to antibiotics and other drugs will result in the deaths of an additional 10 million people each year worldwide by 2050 and cost the global economy up to US$100tn, projects a UK report.

  • AS Saliva Orthana drug tariff change Subscription

    11 DEC 2014 10:48

    AS Saliva Orthana 50ml and 500ml sprays are now CE marked medical devices listed in Part IXA of the Drug Tariff. The AS Saliva Orthana product entry has been removed from Part XV (Borderline substances) of the Drug Tariff. This does not apply, however, to AS Orthana Lozenges and a separate entry will be reinstated under artificial saliva substitutes in the Part XVIIA of the January Drug Tariff. This will not affect reimbursement. 

  • Capoten interactions Subscription

    11 DEC 2014 13:27

    The summary of product characteristics of Capoten (captopril; Bristol-Myers Squibb) now states that this medicine should not be used with aliskiren-containing products in patients with diabetes or renal impairment. In addition, dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is not recommended. 

  • Cerdelga approved by CHMP Subscription

    11 DEC 2014 11:09

    The Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency, has recommended granting a marketing authorisation for Cerdelga (eliglustat; Genzyme), an orphan medicine for the treatment of Gaucher disease type 1. 

  • Chief pharmacists warned of the urgent need for succession planning as a large number of NHS pharmacists across the UK responsible for spending some £5bn on hospital medicines are set to retire in the next 5 years, a recent review concluded

    Chief pharmacists warned of need for succession planning for procurement roles Subscription

    27 NOV 2014 14:05

    Succession planning is urgently needed to prepare for the swathe of experienced pharmacists buying medicines for hospitals who will shortly retire, an independent review has warned.

  • Depo-Provera stock issues Subscription

    19 DEC 2014 15:27

    Stock of Depo-Provera (medroxyprogesterone acetate; Pfizer) 150mg/ml will be exhausted by 25 December 2014. The company anticipates that supply will resume in the week commencing 12 January 2015. Medical information on 01304 616161. Further information on 0845 6088866.   

  • Duaklir Genuair now available Subscription

    12 DEC 2014 11:30

    Duaklir Genuair (aclidinium bromide and formoterol fumarate) dry powder inhaler 340μg/12μg is now available from AstraZeneca for use as a maintenance brochodilator to relieve symptoms of chronic obstructive pulmonary disease in adults. Net price: 1 x 60-dose inhaler, £32.50.

  • The aides aegypti or yellow fever mosquito transmits the yellow fever virus. The yellow fever virus causes deaths in 20-50% of unvaccinated patients and induces changes in the expression of some 800 genes, recent study finds

    Early effects of yellow fever virus examined Subscription

    10 DEC 2014 10:08

    In the first 72 hours after infection, the yellow fever virus induces changes in the expression of nearly 800 genes, scientists have discovered.

  • Clinical trials of the VSV-ZEBOV Ebola vaccine have been halted because some participants developed joint pain after receiving the injection, says a press release issued by the University Hospitals of Geneva

    Ebola clinical trial suspended after volunteers complain of joint pains Subscription

    12 DEC 2014 16:49 By Joanna Lyford

    A phase I clinical trial of the fast-tracked Ebola vaccine VSV-ZEBOV has been halted in Switzerland because some trial participants developed mild joint pain.

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.